The research team has been working on something exciting in the endeavor to streamline the proposal process.

Previously, the intent to submit a proposal was done through a series of emails. The proposal intake form will allow a more organized way of collecting proposal data needed for any upcoming submissions.

Link to Proposal Submission Intake Form 

The form launch will be announced at the next stand-up meeting, and a link to the form will be on the CPH Research SharePoint site. Let a research team member know if you have any suggestions on how the form may be improved.

NIH T32 grant entitled “Translational Research in Alzheimer’s and Related Dementias (TRIAD)” will have 2 predoc slots and 1 postdoc slot open for appointment on September 1, 2022 or later. Applications for support are due on August 15, 2022.

The emphasis of the grant is on providing cross-disciplinary training from bench to bedside, ie., spanning the discovery continuum from molecular/biochemical approaches, preclinical translational approaches, and clinical research. The thematic focus is on risk factors for dementia, including cerebrovascular disease, neuroinflammation, Down syndrome and traumatic brain injury. Many other risk factors or lifestyle interventions that affect dementia risk could also qualify. Trainees with diverse research backgrounds beyond standard wet-lab neuroscience, such as bioinformatics, biostatistics, engineering, epidemiology, social sciences, engineering, and community based and human research studies, are strongly encouraged to apply.

If you have any questions or would like to discuss the T32 in more detail, please contact: Linda Van Eldik, 7-5566, [email protected] or Paul Murphy, 8-3811, [email protected] 

Purpose: The University of Kentucky Women and Philanthropy Network is accepting applications for its grants program. In 2007, a group of women came together with a common vision – to build a better UK and Commonwealth. Each year membership contributions are pooled to support the University, its students, research and programs by awarding funds through grants.

Colleges and programs are asked to coordinate proposal requests with the dean of their college or appropriate vice president to whom the program reports. The top 10 proposals will be offered the opportunity to present to the Leadership Council of Women and Philanthropy November 3, 2022. Funding will be available in January 2023 to be used by August 1, 2024.

Eligibility: University faculty and students are eligible. Students must be enrolled at UK and be in good standing. Eligible students include undergraduate, graduate and professional degree students. Transfer and non-traditional students via traditional and alternative paths are eligible.

Funding Amount/ Project Period: up to $50,000 for 1 year

Institutional Limit:  2 per college or program

Internal Competition: Internal coordination will be handled at the college or vice president level. Individuals interested in this program should contact their associate dean for research or the office of the responsible vice president for research as soon as possible.

For questions, email [email protected].

Agency Deadline: July 31, 2022

Agency: Robert Wood Johnson Foundation

Description: Systems for Action (S4A) is a signature research program of the Robert Wood Johnson Foundation (RWJF) that helps to build the evidence base for a Culture of Health by rigorously testing new ways of connecting the nation’s fragmented medical, social, and public health systems. New strategies and tools are needed to help medical, social, and public health systems work together to dismantle structural racism and improve health and well-being for all.

Each study supported by the S4A program must examine a novel approach to systems alignment that engages actors from medical care, public health, and social services systems in collaborative efforts to dismantle structural and systemic racism and improve health equity. The systems alignment approach to be studied must engage all three types of systems implicated in the S4A research agenda—medical care, public health, and social services. Studies that focus narrowly on initiatives that operate primarily within the medical care system are not appropriate for this CFP.

This 2022 CFP offers two distinct categories of research awards:

1. Developmental Studies: This award will support pilot testing of the proposed systems alignment approach in order to examine its feasibility and acceptability for actors in the relevant medical, social, and public health systems, and its potential to dismantle forms of structural racism and inequity embedded within these systems. This award category is for applicants who have not previously completed a pilot study of their proposed systems alignment approach and do not yet have preliminary evidence about the feasibility of implementing the approach and the feasibility of related research strategies. The pilot studies supported by this award should also test the feasibility of key research strategies to be used, including issues related to participant recruitment and retention, data exchange and linkage, measurement strategies, and random assignment or other statistical control methods if applicable. This award will provide up to $100,000 in total funding to be used over a 12-month period to pilot test the proposed system alignment approach.

1. Impact Studies: This award will support studies that examine the impact of the proposed system alignment strategy on relevant measures of health and health equity, with a focus on understanding the strategy’s success or failure in dismantling forms of structural racism and inequity embedded within systems. This award will provide up to $500,000 in total funding to be used over a 36-month period to study the impact of the proposed system alignment approach on relevant measures of health and health equity. This award category is open only to applicants who have completed a pilot study of their proposed system alignment approach and can provide results that confirm the feasibility of the approach and its acceptability to key actors within the relevant medical, social, and public health systems. Applicants must provide documentation of pilot test results as part of their application, which may include a publication, report, working paper, or research brief.

An applicant webinar will be held on August 15, 2022 (3PM ET). 

Registration is required through this link.

Closing Date: Letter of Intent (required): September 6, 2022, Full Proposal: October 5, 2022

Description: The goal of this funding opportunity announcement (FOA) is to seeks research to promote rapid development of analytical methods and tools to assess the prevalence of emerging illicit drugs and thereby understand their health impacts.

By promoting research to develop peer-reviewed analytical and point of care assays for new drugs and metabolites, NIH intends that awardees can greatly reduce the cost of validated assay implementation and ensure the methods become standards at “sentinel” labs and clinical sites that employ them. Importantly, the initiative design builds in the flexibility to modify the target analytes over time to allow a rapid responses to changing opioid threat conditions.

Announcement Number: RFA-DA-23-045

Closing Date: February 2, 2023

Description: Specifically, NIDA seeks applications for multi-project RM1 Opioid Use Disorder Quality Measurement and Management Research Centers (OUD-QM2RCs). OUD-QM2RCs will involve researchers and a partner with a deployed or in-development quality measurement strategy for opioid use disorder treatment that rigorous, scientific research could substantially advance. The ultimate goal is the creation of feasible, efficient quality measurement systems that provide meaningful information to help patients, families, and payors fairly compare and select providers and to help clinicians and providers improve patient outcomes. OUD-QM2RCs should 1. identify key aspects of the partner’s strategy that require additional research, 2. conduct the research, and 3. test or prepare to test the resulting system to determine if implementing it improves patient outcomes. Activities should also support the acceptability of the quality measurement and management system to patients, clinicians, and providers; the feasibility, scalability, and sustainability of the system; and equity in clinician/provider selection and treatment delivery.

Announcement Number: RFA-DA-23-046

Closing Date: February 2, 2023

First Available Due Date: October 01, 2022

Expiration Date: October 02, 2022

Related Announcements: PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Purpose: The participating Institutes and Centers (ICs) are inviting applications to expand existing awards that are not currently focused on Alzheimer’s disease and its related dementias (AD/ADRD)—frontotemporal dementia, Lewy body dementia, Vascular Contributions to Cognitive Impairment and Dementia (VCID), and multiple etiology dementias—to allow the research to develop such a focus. Active awards with project end dates in FY 2024 or later are eligible. The award may not be in a terminal no-cost extension or going into a no-cost extension in FY 2023. Please note that a few ICs limit no-cost extensions in the final non-competing year of an award. For that reason, it is important to contact staff at the IC supporting the award when planning the request.

As administrative supplements, the work proposed needs to be within the scope of the research or training that is already supported. Center awards and resource awards are most likely to be able to justify these supplements, as they tend to have a broad content scope. Some research grants will also qualify if the current research is on a related topic (such as cognitive decline in aging, caregiving, the biology of neurodegeneration, genetics, imaging, computational methods, pain perception, or biostatistical tools that have application to research on AD/ADRD). NIA hosts a website that provides details on how Alzheimer’s disease and its related dementias are defined and some examples of currently supported research. Awardees are expected to seek competing support to continue promising leads from the research supported through the supplement.

Additional information on areas of interest and funding opportunity announcements can be found here: Funding Opportunities | National Institute on Aging (nih.gov).

Description: The National Institute on Drug Abuse (NIDA) seeks collaborative research by multi-disciplinary teams to address critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, health services, HIV/AIDS and co-occurring opportunistic infections (e.g., viral hepatitis C, tuberculosis, sexually transmitted infections) and associated consequences in substance abusing populations, medication development, or other research areas relevant to drug abuse.

Activity Code: P01 Research Program Projects

Announcement Number: PAR-22-201

Closing Date: September 25, 2022

Purpose: The purpose of this Notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into health care settings. This Notice is to encourage intervention research focused on addressing exposure to violence - including but not limited to child maltreatment, intimate partner violence/teen dating violence, elder mistreatment, peer violence/bullying, and community violence – to improve individual-level health processes and outcomes.

Release Date: July 8, 2022

First Available Due Date: September 07, 2022

Expiration Date: October 05, 2025

Related Announcements

PA-20-183 NIH Research Project Grant (Parent R01 Clinical Trial Required)

PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

PA-20-144 Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)

PA-20-141 Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 Clinical Trial Optional)

PA-20-145 Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)

PAR-22-156 Alcohol Health Services Research (R01 Clinical Trial Optional)

PAR-22-158 Alcohol Treatment and Recovery Research (R01 Clinical Trial Required)

PA-21-110 Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)

PA-21-180 Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)

PAR-21-317 NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

PAR-21-063 NIDCD low risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)

PAR-21-358 Risk and Protective Factors of Family Health and Family Level Interventions (R01 Clinical Trial Optional)

PAR-22-145 Leveraging Health Information Technology to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional)

PAR-21-081 Addressing Health Disparities Among Immigrant Populations through Effective Interventions (R01 Clinical Trial Optional)

PAR-20-310 Health Services Research on Minority Health and Health Disparities (R01- Clinical Trial Optional)

PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

PAR-22-094 Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)

PAR-22-093 Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)

PAR-20-150 NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)

PAR-22-105 Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

PAR-22-109 Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)